Gallin J I, Wright D G, Malech H L, Davis J M, Klempner M S, Kirkpatrick C H
Ann Intern Med. 1980 Apr;92(4):520-38. doi: 10.7326/0003-4819-92-4-520.
Recent advances in understanding the physiologic and biochemical bases for recruitment of phagocytes to inflammatory sites has led to the recognition of patients who have recurrent infections because of abnormalities of phagocyte chemotaxis. In some of these patients there is abnormal chemoattractant mediator production or regulation, whereas in others there are defects in phagocytic cell function. The cellular defects in chemotaxis can be characterized as either intrinsic defects of the cellular motility apparatus or acquired defects from mediators influencing cell function or from shifts in circulating phagocyte subpopulations. Systematic study of these defects has resulted in functional, biochemical, and ultrastructural characterization of abnormal phagocyte chemotaxis in certain patients, and in some patients study has led to rational approaches for treatment. Clinical trials assessing the efficacy of such pharmacologic agents are underway.
在理解吞噬细胞募集至炎症部位的生理和生化基础方面的最新进展，已使人们认识到那些因吞噬细胞趋化性异常而反复感染的患者。在这些患者中，有些存在趋化因子介质产生或调节异常，而另一些则存在吞噬细胞功能缺陷。趋化性的细胞缺陷可被特征化为细胞运动装置的内在缺陷，或因影响细胞功能的介质或循环吞噬细胞亚群的改变而获得的缺陷。对这些缺陷的系统研究已导致某些患者异常吞噬细胞趋化性的功能、生化和超微结构特征得以明确，并且在一些患者中，研究已带来合理的治疗方法。评估此类药物疗效的临床试验正在进行中。
